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Tomography as a Prognostic
Indicator of Cardiac SarcoidosisWe thank Dr. Eguchi and colleagues you for their interest in our
paper (1). Our study was not designed to evaluate the effect of
treatment on the positron emission tomography (PET)/computed
tomography (CT) results. For patients who had multiple PET/CT
scans, we only included the initial scan results. Nevertheless, during
the baseline PET/CT study, 26% of the patients were treated
with corticosteroids. Although we agree that treatment can reduce
inﬂammation, such an effect would only minimize the association
identiﬁed in our study; thus, if no steroids were used at baseline, thedifferences in outcomes between the groups may be even larger. We
agree that PET can be useful for assessing the response to therapy,
and our group recently showed that a reduction in the amount of
inﬂammation, as assessed by using serial PET/CT studies, is
associated with improved left ventricular ejection fraction (2).
When we used the updated (2006) Japanese guidelines, signiﬁ-
cant discordance remained between these criteria and the PET/CT
results. Implantable cardioverter-deﬁbrillator implantations were
performed at the discretion of the treating physicians for both
primary and secondary prevention of sudden cardiac death.
Our laboratory and others have used a fast of at least 3 h after
a high-fat, low-carbohydrate diet. In considering the validity
of this approach, we would note that our rate of diffuse F-18 ﬂu-
orodeoxyglucose uptake is low and similar to that reported by
others (3). Our center has used various diets (including a longer
period of fasting), and we have detected no signiﬁcant differences
in suppression of F-18 ﬂuorodeoxyglucose from the normal myo-
cardium with these different approaches.
With regard to the higher yield of endomyocardial biopsy among
patients with abnormal PET/CT results, we believe that patients
with positive imaging ﬁndings are more likely to have signiﬁcant
disease and, therefore, are more likely to have positive biopsy re-
sults. Although image-guided biopsy may improve the diagnostic
yield, it is essential for clinicians to know that the sensitivity of
endomyocardial biopsy is extremely low. Therefore, it is not
uncommon for patients with negative results on endomyocardial
biopsy to have cardiac involvement.
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